Immune response to COVID-19 ;Predicting Susceptibility
Lead Participant:
ALCYOMICS LIMITED
Abstract
Extension For Impact Funding
Our results to date have shown that within the general population there are responders, mild or non responders to the COVID-19 virus. This will allow us to identify those individuals who may respond well to a vaccine and those individuals that may need further, or additional, therapy for COVID-19.
The extension for impact funding will allow us to validate these results on cohorts of asymptomatic or mildly effected individuals and those who acquired more severe disease. A pattern of molecules, cytokine/chemokines, or genes will be validated on COVID-19 patient samples and further aid in drug discovery and vaccine development.
Our results to date have shown that within the general population there are responders, mild or non responders to the COVID-19 virus. This will allow us to identify those individuals who may respond well to a vaccine and those individuals that may need further, or additional, therapy for COVID-19.
The extension for impact funding will allow us to validate these results on cohorts of asymptomatic or mildly effected individuals and those who acquired more severe disease. A pattern of molecules, cytokine/chemokines, or genes will be validated on COVID-19 patient samples and further aid in drug discovery and vaccine development.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| ALCYOMICS LIMITED | £75,000 | £ 75,000 |
People |
ORCID iD |
| Anne Dickinson (Project Manager) |